Premium
Pretreatment and early intratreatment prediction of clinicopathologic response of head and neck cancer to chemoradiotherapy using 1 H‐MRS
Author(s) -
King Ann D.,
Yeung David K.W.,
Yu Kwokhung,
Mo Frankie K.F.,
Bhatia Kunwar S.,
Tse Gary M.K.,
Vlantis Alexander C.,
Wong Jeffrey K.T.,
Hu Chenwen,
Ahuja Anil T.
Publication year - 2010
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.22224
Subject(s) - medicine , chemoradiotherapy , head and neck cancer , head and neck squamous cell carcinoma , creatine , radiation therapy , nuclear medicine , head and neck , cancer , magnetic resonance imaging , oncology , radiology , surgery
Purpose: To determine if choline (cho) identified by proton magnetic resonance spectroscopy ( 1 H‐MRS) performed pretreatment and early in the course of treatment predicts clinicopathologic response of head and neck squamous cell carcinoma (HNSCC). Materials and Methods: In all, 60 patients with HNSCC scheduled to undergo concurrent chemoradiotherapy or radiotherapy alone were recruited. 1 H‐MRS was performed pretreatment and early intratreatment (2 weeks after start of treatment). Cho:creatine and cho:water ratios at each timepoint and change in the ratios between the two timepoints were correlated with locoregional failure, distant metastases, overall survival, and cancer‐related death. Statistical analysis was performed using logistic regression and chi‐square and a P ‐value of < 0.05 was considered statistically significant. Results: Cho was identified in 47/49 successful pretreatment spectra and 42 of these 47 underwent successful 1 H‐MRS early intratreatment, of which 21 showed persistent cho. Locoregional failure occurred in 15, distant metastases in 6, and death in 15 patients; the follow‐up period in survivors ranged from 13–64 months (mean, 39 months). No statistically significant correlation was found between 1 H‐MRS parameters and clinical endpoints. Conclusion: The pretreatment cho and change in cho early during a course of treatment did not predict clinical outcome. J. Magn. Reson. Imaging 2010;32:199–203. © 2010 Wiley‐Liss, Inc.